Novo Nordisk shares dive 9% after heart medicine fails trial

Business Archived • July 31, 2026 • 3 views

The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.

Source: https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=100003114 - Read Original